Dapagliflozin for Long COVID Syndrome

What this study is about

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Who can join (things the study team will check)

✅ You may be able to join if…

• 18 years of age or older and willing and able to provide informed consent
• Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.
• New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).
• Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.

🚫 You may not be able to join if…

• History of diabetes
• Prior heart failure
• Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)
• Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.
• Women who are breastfeeding
• Severe renal impairment (eGFR<30mL/min1.73m2)
• Known history of allergy or hypersensitivity to dapagliflozin Exclusion for optional MRI portion of the protocol:
• Any contraindication to MRI

Where this trial is running

• University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Who to contact

Poppy Dr. Ian Paterson · 1-613-696-7000 · dpaterson@ottawaheart.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06907251.